🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PARASOL news from the Scientific Workshop with U.S. FDA. Stay tuned for more updates at #KidneyWk2024! (translational session at 4:30 Friday 10/25) #FSGS #KidneyHealth #ResearchRevolution eu1.hubs.ly/H0d2BZl0 NephCure National Kidney Foundation Michigan Kidney Translational Med. Center (MiKTMC) American Society of Nephrology

Missed the PARASOL Scientific Workshop? Learn about the findings on FSGS endpoints American Society of Nephrology #KidneyWk from Laura Mariani, Prof Danny Gale, Abigail Smith, Aliza Thompson, Josh Tarnoff and Christine B. Sethna, MD EdM. Session Friday, poster Saturday eu1.hubs.ly/H0d6WtH0

Thrilled to debut this episode about genetic testing in kidney disease. Pair with the piping hot AJKD Core Curriculum on the topic Neera Dahl Abe Aron for a 3 hour crash course ajkd.org/article/S0272-…

Proteinuria reduction is key in slowing the progression of IgA nephropathy and FSGS. Discover the latest strategies to prevent kidney failure from Loreto Gesualdo, Sian Griffin 🏴󠁧󠁢󠁷󠁬󠁳󠁿 🌻 🇺🇦 🌻 🏳️‍⚧️, and Pierre-Louis THARAUX: ow.ly/4J9S50TQPnl #KidneyWeek2024 #ASNKidney #ASN

We look forward to sharing our latest research in #RareKidneyDisease, including #IgAnephropathy and #FSGS at #KidneyWk 2024. Our presentations will highlight new data from the SPARTAN and SPARTACUS Studies, provide an analysis from the PROTECT Study examining the effect of

“People don’t come to us as a heart or a kidney or a liver; they come to us as a whole person”—Katherine Tuttle 🫘 🫀 Hear more of her thoughts on the new #KidneyCompass podcast that I cohost with Brendon Neuen , now live on Spotify! open.spotify.com/episode/6fSgJO…

Sparsentan in Patients with Prior or Concurrent Immunosuppressive Treatment (IST) for 🔬 IgA Nephropathy (IgAN): A Case Series from Pablo Garcia #Nephpearls #KidneyWk

Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors (SGLT2i) in Adults with 🔬 IgA Nephropathy (IgAN) in the Ongoing Phase 2 SPARTACUS Trial #Nephpearls #KidneyWk

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Adults With 🔬 IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE) #Nephpearls #KidneyWk

Sparsentan in Combination with Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN): A Case Series #Nephpearls #KidneyWk

Not all CKD etiologies are the same: Despite having a lower relative risk of hospitalization, CVD events and mortality, patients with IgAN and FSGS are at higher risk of CKD progression than the most common etiologies of CKD. onlinelibrary.wiley.com/doi/10.1111/jo…